Steven Brown
Internal Medicine · Minden, NVNPI 1659459873
Payments from drug & device makers
Across 79 payments — averaging $26.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$577
- Novo Nordisk$209
- Novartis$207
- AstraZeneca$198
- Amgen$177
- Boehringer Ingelheim$112
- plus $600 from 14 others
What the payments were for
- Food & beverage$2,080100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 20 | $577 |
| Novo Nordisk | 12 | $209 |
| Novartis | 5 | $207 |
| AstraZeneca | 5 | $198 |
| Amgen | 4 | $177 |
| Boehringer Ingelheim | 6 | $112 |
| Stryker | 3 | $93 |
| Bayer | 4 | $80 |
| Astellas Pharma US Inc | 3 | $76 |
| Pfizer | 2 | $53 |
| Idorsia Pharmaceuticals US Inc | 2 | $43 |
| AbbVie | 2 | $39 |
| Johnson & Johnson | 2 | $37 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| Dynavax Technologies Corporation | 2 | $33 |
| Almatica Pharma LLC | 1 | $26 |
| Abbott | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Merck | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
- TRELEGY ELLIPTA$125
- EVENITY$119
- ENTRESTO$116
How this compares
$2,080 in reported general payments places this provider in the 80th percentile of 1,071 internal medicine providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 95 | $113,481 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $77,458 |
| JardianceEmpagliflozin | 25 | $33,735 |
| JanuviaSitagliptin Phosphate | 41 | $33,644 |
| TivicayDolutegravir Sodium | 13 | $28,840 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $25,595 |
| XareltoRivaroxaban | 16 | $22,752 |
| MyrbetriqMirabegron | 29 | $19,685 |
| OzempicSemaglutide | 15 | $18,233 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 54 | $15,945 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $14,725 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $12,893 |
| Spiriva RespimatTiotropium Bromide | 19 | $12,262 |
| TrulicityDulaglutide | 13 | $12,074 |
| Advair HfaFluticasone Propion/Salmeterol | 24 | $11,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $53 | $113,48195 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $577 | $97,442108 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $112 | $58,89063 claims |
| MerckJanuvia | $19 | $33,64441 claims |
| Johnson & JohnsonXarelto | $37 | $22,75216 claims |
| Astellas Pharma US IncMyrbetriq | $76 | $19,68529 claims |
| Novo NordiskOzempic | $209 | $18,23315 claims |
| AbbVieLinzess | $39 | $8,85215 claims |
| AstraZenecaBrilinta | $198 | $7,89013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,071 internal medicine providers in Nevada.
Other internal medicine in Minden
- Darin BrimhallLas Vegas$39.7M
- Alton WaltersLas Vegas$8.9M
- Michael JacobsLas Vegas$8.1M
- Nirupa PaulrajLas Vegas$5.8M
- Atoya AdamsLas Vegas$5.4M
- Roger EstevezLas Vegas$3.7M
- Syed PervaizLas Vegas$3.1M
- Marigene Salazar SharmaHenderson$2.5M
- Mavis MatsumotoHenderson$1.8M
- Vrijendra HoonLas Vegas$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.